Article
Medicine, General & Internal
Tapio Paljarvi, Julian Forton, Sierra Luciano, Kimmo Herttua, Seena Fazel
Summary: This study found that patients with asthma or allergic rhinitis had increased odds of adverse neuropsychiatric outcomes after montelukast initiation.
Article
Pharmacology & Pharmacy
Ryogo Umetsu, Mizuki Tanaka, Yoko Nakayama, Yamato Kato, Natsumi Ueda, Yuri Nishibata, Shiori Hasegawa, Kiyoka Matsumoto, Noriaki Takeyama, Kazuhiro Iguchi, Hiroyuki Tanaka, Eiichi Hinoi, Naoki Inagaki, Masatoshi Inden, Yoshinori Muto, Mitsuhiro Nakamura
Summary: This study investigated the association between montelukast and neuropsychiatric adverse events, finding significant reporting odds ratios for suicidal ideation and depression. Functional enrichment analysis revealed multiple genes interacting with montelukast and involved in neuroactive ligand-receptor interactions. The study suggests a need for further research on the pharmacological mechanisms underlying montelukast-associated neuropsychiatric symptoms.
FRONTIERS IN PHARMACOLOGY
(2021)
Editorial Material
Clinical Neurology
Richard M. Camicioli, Carlo Colosimo
Summary: This study examined the association between different NPS profiles and the risk of cognitive decline in PD-MCI patients, which is of great importance for the diagnosis and management of PD-MCI patients.
Article
Pediatrics
Abdullah Al-Shamrani, Saleh Alharbi, Sumayyah Kobeisy, Suzan A. AlKhater, Haleimah Alalkami, Turki Alahmadi, Aisha Almutairi, Adel S. Alharbi, Abdullah A. Yousef
Summary: This article studied the safety profile of montelukast in children and found that adverse neuropsychiatric and sleep-related drug reactions were more prevalent. Sleep disturbance, agitation, pain, and hyperactivity were the most common adverse reactions. Pediatricians need to be aware of these adverse reactions and conduct research on risk management.
Article
Environmental Sciences
Manuela Tondelli, Annalisa Chiari, Giulia Vinceti, Chiara Galli, Simone Salemme, Tommaso Filippini, Chiara Carbone, Claudia Minafra, Claudia De Luca, Riccardo Prandi, Simona Tondelli, Giovanna Zamboni
Summary: This study explores the relationship between greenness and neuropsychiatric symptoms in individuals with dementia. The findings suggest that green environments may have an impact on the mental well-being of people with dementia.
ENVIRONMENTAL RESEARCH
(2024)
Article
Pharmacology & Pharmacy
Daniela Poblete, Fernando Bernal, Gabriel Llull, Sebastian Archiles, Patricia Vasquez, Leonardo Chanqueo, Nicole Soto, Maria A. Lavanderos, Luis A. Quinones, Nelson M. Varela
Summary: UGT1A1*28 and CYP2B6 c.516G>T genetic polymorphisms were found to be associated with moderate-to-severe hyperbilirubinemia and CNS toxicity in HIV patients treated with ATV or EFV at San Juan de Dios Hospital in Chile. Larger prospective studies are needed to validate these associations in the population.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Lucy L. Gibson, Lea T. Grinberg, Dominic Ffytche, Renata E. P. Leite, Roberta D. Rodriguez, Renata E. L. Ferretti-Rebustini, Carlos A. Pasqualucci, Ricardo Nitrini, Wilson Jacob-Filho, Dag Aarsland, Claudia K. Suemoto
Summary: In a post mortem study on LBD, hallucinations were found to be associated with higher LB Braak stages, while higher NFT Braak staging was associated with depression, agitation, and greater number of symptoms. Patients with dual AD+LBD pathology had the highest risk of hallucinations, agitation, apathy, and total symptoms.
ALZHEIMERS & DEMENTIA
(2023)
Article
Oncology
Maria Antonietta Barbieri, Emanuela Elisa Sorbara, Giulia Russo, Giuseppe Cicala, Tindara Franchina, Mariacarmela Santarpia, Nicola Silvestris, Edoardo Spina
Summary: Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms primarily occurring in the stomach. Most cases of GISTs are associated with activating mutations in the KIT and PDGFRA genes. The approval of tyrosine kinase inhibitors (TKIs) has significantly improved the treatment of GISTs, and the analysis of adverse drug reactions (ADRs) through spontaneous reporting systems is important for understanding the safety profile of these drugs.
Article
Oncology
Maria Antonietta Barbieri, Giulia Russo, Emanuela Elisa Sorbara, Giuseppe Cicala, Tindara Franchina, Mariacarmela Santarpia, Desiree Speranza, Edoardo Spina, Nicola Silvestris
Summary: This study aimed to assess the neuropsychiatric adverse drug reactions (ADRs) of new oral tyrosine kinase inhibitors (TKIs) in metastatic colorectal cancer (mCRC) patients. By analyzing the reports in the FDA Adverse Event Reporting System (FAERS), new potential neuropsychiatric ADRs were identified. Further investigations are needed to define the neurotoxicity of TKIs in mCRC patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Benjamin D. McNeil
Summary: Adverse reactions to therapeutic drugs are thought to be triggered by patient-specific IgE antibodies recognizing drug molecules, but another proposed mechanism involves direct mast cell degranulation activation via MRGPRX2 receptor. Mild-to-moderate events triggered by MRGPRX2 activation may be more common than currently appreciated, even after administration of high doses for some drugs.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Psychiatry
Wei Hua, Sen Wang, Xi Wang, Ying Shao, Yali Wang, Jiangzhu Ye, Bin Su, Taiyi Jiang, Tong Zhang, Hao Wu, An Liu, Qunhui Li, Supriya D. Mahajan, Zaicun Li, Lijun Sun, Lili Dai
Summary: The study found that the prevalence of anxiety, depression, and sleep disturbances decreased significantly after 12 months of EFV treatment, indicating a positive impact on improving neuropsychiatric adverse events. Additionally, risk factors such as low education level, low income, unemployment, divorce, and WHO III/IV stages were associated with severe neuropsychiatric disorders.
FRONTIERS IN PSYCHIATRY
(2021)
Review
Behavioral Sciences
Simona Karamazovova, Veronika Matuskova, Zahinoor Ismail, Martin Vyhnalek
Summary: In addition to motor coordination, the cerebellum also plays an important role in cognitive and affective processes. Spinocerebellar ataxias (SCA) and Friedreich ataxia (FRDA) are rare neurodegenerative diseases of the cerebellum that not only affect motor functions but also have cognitive and neuropsychiatric symptoms. This review discusses the prevalence, clinical features, and treatment approaches of neuropsychiatric impairments such as depression, anxiety, apathy, agitation, impulse dyscontrol, and psychosis in SCA and FRDA patients. Further research is needed to improve the detection and treatment options for these co-morbidities in ataxia patients due to their significant impact on quality of life.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2023)
Article
Neurosciences
Kaicheng Li, Qingze Zeng, Xiao Luo, Shile Qi, Xiaopei Xu, Zening Fu, Luwei Hong, Xiaocao Liu, Zheyu Li, Yanv Fu, Yanxing Chen, Zhirong Liu, Vince D. Calhoun, Peiyu Huang, Minming Zhang
Summary: The study found that concomitant neuropsychiatric symptoms are associated with accelerated Alzheimer's disease progression. Using multimodal brain imaging, a pattern associated with these symptoms was identified and found to be correlated with the development of Alzheimer's disease. The pattern was also found to be associated with multiple cognitive domains and could predict cognitive decline.
HUMAN BRAIN MAPPING
(2023)
Article
Allergy
Veronica Sansing-Foster, Nicole Haug, Andrew Mosholder, Noelle M. Cocoros, Marie Bradley, Yong Ma, Dinci Pennap, Elizabeth C. Dee, Sengwee Toh, Ella Pestine, Andrew B. Petrone, Ivone Kim, Jennifer G. Lyons, Efe Eworuke
Summary: The study found no associations between montelukast use and hospitalizations for depression or self-harm events compared to ICS use. Most psychiatric adverse events occurred in patients with a past psychiatric history.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Review
Endocrinology & Metabolism
Anne-Sophie C. A. M. Koning, Merel van der Meulen, Daphne Schaap, Djaina D. Satoer, Christiaan H. Vinkers, Elisabeth F. C. van Rossum, Wouter R. van Furth, Alberto M. Pereira, Onno C. Meijer, Olaf M. Dekkers
Summary: The proportion of neuropsychiatric adverse effects in patients using synthetic glucocorticoids is high, with depression and mania being the most significant associations. Awareness of possible psychiatric side effects is essential when starting glucocorticoid treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)